NCT02758717View on ClinicalTrials.gov

Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

May 13, 2016

Primary Completion Date

August 13, 2019

Study Completion Date

September 13, 2025

Conditions
Ann Arbor Stage IB Hodgkin LymphomaAnn Arbor Stage II Hodgkin LymphomaAnn Arbor Stage IIA Hodgkin LymphomaAnn Arbor Stage IIB Hodgkin LymphomaAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage IIIA Hodgkin LymphomaAnn Arbor Stage IIIB Hodgkin LymphomaAnn Arbor Stage IV Hodgkin LymphomaAnn Arbor Stage IVA Hodgkin LymphomaAnn Arbor Stage IVB Hodgkin LymphomaClassic Hodgkin Lymphoma
Interventions
DRUG

Brentuximab Vedotin

Given IV

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (9)

10016

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

20007

MedStar Georgetown University Hospital, Washington D.C.

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

43210

Ohio State University Comprehensive Cancer Center, Columbus

55905

Mayo Clinic, Rochester

63110

Washington University School of Medicine, St Louis

77030

M D Anderson Cancer Center, Houston

94304

Stanford Cancer Institute Palo Alto, Palo Alto

07601

Hackensack University Medical Center, Hackensack

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER